Replimune (REPL) Shares Rise on IGNYTE Trial Durable Survival Data

Replimune Group plc (NASDAQ: REPL) reported on May 30, 2026, that its IGNYTE clinical trial of RP1 in combination with nivolumab demonstrated a durable survival benefit in patients with anti-PD1-refractory advanced melanoma. The study met its primary endpoint of overall survival, showing a statistically significant improvement. The company stated that specific data from the pivotal trial will be presented at an upcoming medical meeting and that it plans to submit the results to the U.S. Food and Drug Administration for potential accelerated approval. No new safety concerns were reported. Replimune’s lead asset, RP1, is an oncolytic immunotherapy designed to directly kill tumor cells and activate a systemic anti-tumor immune response. The positive readout bolsters the company’s pipeline amid heightened interest in novel oncology approaches. REPL shares climbed 15% in pre-market trading.